Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.11851/8352
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTufan, Müge Aydın-
dc.contributor.authorErsözlü, Emine Duygu-
dc.contributor.authorKöseoğlu, Hamide Kart-
dc.contributor.authorYücel, Ahmet Eftal-
dc.date.accessioned2022-01-15T13:02:37Z-
dc.date.available2022-01-15T13:02:37Z-
dc.date.issued2021-
dc.identifier.issn2602-3032-
dc.identifier.issn2602-3040-
dc.identifier.urihttps://doi.org/10.17826/cumj.914892-
dc.identifier.urihttps://hdl.handle.net/20.500.11851/8352-
dc.description.abstractPurpose: Methotrexate (MTX) is still the main treatment option for rheumatoid arthritis (RA). There is no consensus on drug administration routes and dosage when administered alone or in combination with other drugs. This study aims to identify the effects of early administration of a combination therapy containing high dose subcutaneous (SC) MTX on RA management. Materials and Methods: Forty-five patients with RA who newly diagnosed were divided into two groups randomly. The patients who took 12.5 mg SC MTX per week in the first 4 weeks defined as a low dose group. The patients who took 25 mg SC MTX per week in the first 4 weeks defined as a high dose group. Then, patients of both groups continued with 12.5 mg oral MTX per week. Clinical and laboratory findings, disease activity scores and response rates of the patients were recorded at the beginning, 3rd months and 6th months. Results: There was no significant difference between the two groups at 3rd month's values. There were statistically significant improvements at 6th month's values. Values were as follows in low and high dose groups: mean DAS28-CRP (3.5 vs 2.7), VAS pain score (3.3 vs 1.6), and TJC28 (3 vs 1.5), respectively. Conclusion: Early administration of high-dose SC MTX effectively controls disease activity and increases the quality of life in RA patients.en_US
dc.language.isoenen_US
dc.publisherCukurova Univ, Fac Medicineen_US
dc.relation.ispartofCukurova Medical Journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDrug administration routesen_US
dc.subjectmethotrexateen_US
dc.subjectrheumatoid arthritisen_US
dc.subjectDrug-Therapyen_US
dc.subjectCombinationen_US
dc.subjectAssociationen_US
dc.subjectReliabilityen_US
dc.subjectMonotherapyen_US
dc.subjectEtanercepten_US
dc.subjectDiagnosisen_US
dc.subjectValidityen_US
dc.subjectModerateen_US
dc.subjectVersionen_US
dc.titleEffect of Subcutaneous High-Dose Methotrexate Treatment on the Management of Rheumatoid Arthritisen_US
dc.typeArticleen_US
dc.departmentFaculties, School of Medicine, Department of Internal Medical Sciencesen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümütr_TR
dc.identifier.volume46en_US
dc.identifier.issue3en_US
dc.identifier.startpage1150en_US
dc.identifier.endpage1159en_US
dc.identifier.wosWOS:000695272700034en_US
dc.institutionauthorKöseoğlu, Hamide Kart-
dc.identifier.doi10.17826/cumj.914892-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
item.openairetypeArticle-
item.languageiso639-1en-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:Dahili Tıp Bilimleri Bölümü / Department of Internal Medical Sciences
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

138
checked on Dec 23, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.